Furukawa T A, Watanabe N, Churchill R
Nagoya City University Graduate School of Medical Sciences, Dept of Psychiatry & Cognitive-Behavioural Medicine, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan, 467-8601.
Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD004364. doi: 10.1002/14651858.CD004364.pub2.
Panic disorder can be treated with pharmacotherapy, psychotherapy or in combination, but the relative merits of combined therapy have not been well established.
To review evidence concerning short- and long-term advantages and disadvantages of combined psychotherapy plus antidepressant treatment for panic disorder with or without agoraphobia, in comparison with either therapy alone.
The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 11/10/2005, together with a complementary search of the Cochrane Central Register of Controlled Trials and MEDLINE, using the keywords antidepressant and panic. A reference search, SciSearch and personal contact with experts were carried out.
Two independent review authors identified randomised controlled trials comparing the combined therapy against either of the monotherapies among adult patients with panic disorder with or without agoraphobia.
Two independent review authors extracted data using predefined data formats, including study quality indicators. The primary outcome was relative risk (RR) of "response" i.e. substantial overall improvement from baseline as defined by the original investigators. Secondary outcomes included standardised weighted mean differences in global severity, panic attack frequency, phobic avoidance, general anxiety, depression and social functioning and relative risks of overall dropouts and dropouts due to side effects.
We identified 23 randomised comparisons (representing 21 trials, 1709 patients), 21 of which involved behaviour or cognitive-behaviour therapies. In the acute phase treatment, the combined therapy was superior to antidepressant pharmacotherapy (RR 1.24, 95% confidence interval (CI) 1.02 to 1.52) or psychotherapy (RR 1.17, 95% CI 1.05 to 1.31). The combined therapy produced more dropouts due to side effects than psychotherapy (number needed to harm (NNH) around 26). After the acute phase treatment, as long as the drug was continued, the superiority of the combination over either monotherapy appeared to persist. After termination of the acute phase and continuation treatment, the combined therapy was more effective than pharmacotherapy alone (RR 1.61, 95% CI 1.23 to 2.11) and was as effective as psychotherapy (RR 0.96, 95% CI 0.79 to 1.16).
AUTHORS' CONCLUSIONS: Either combined therapy or psychotherapy alone may be chosen as first line treatment for panic disorder with or without agoraphobia, depending on patient preference.
惊恐障碍可采用药物治疗、心理治疗或联合治疗,但联合治疗的相对优势尚未明确确立。
回顾关于伴有或不伴有广场恐惧症的惊恐障碍采用心理治疗加抗抑郁药联合治疗与单独使用任一治疗方法相比的短期和长期优缺点的证据。
于2005年10月11日检索了Cochrane协作抑郁、焦虑和神经症对照试验注册库(CCDANCTR-研究和CCDANCTR-参考文献),同时使用关键词“抗抑郁药”和“惊恐”对Cochrane对照试验中心注册库和MEDLINE进行了补充检索。进行了参考文献检索、科学信息数据库检索并与专家进行了个人联系。
两名独立的综述作者确定了随机对照试验,这些试验比较了联合治疗与成人伴有或不伴有广场恐惧症的惊恐障碍患者中任一单一疗法的疗效。
两名独立的综述作者使用预定义的数据格式提取数据,包括研究质量指标。主要结局是“反应”的相对风险(RR),即根据原始研究者的定义,从基线开始有显著的总体改善。次要结局包括全球严重程度、惊恐发作频率、恐惧回避、一般焦虑、抑郁和社会功能的标准化加权平均差,以及总体退出率和因副作用退出率的相对风险。
我们确定了23项随机对照比较(代表21项试验,1709名患者),其中21项涉及行为疗法或认知行为疗法。在急性期治疗中,联合治疗优于抗抑郁药物治疗(RR 1.24,95%置信区间(CI)1.02至1.52)或心理治疗(RR 1.17,95%CI 1.05至1.31)。联合治疗因副作用导致的退出人数比心理治疗更多(伤害所需人数(NNH)约为26)。在急性期治疗后,只要继续使用药物,联合治疗相对于任一单一疗法的优势似乎仍然存在。在急性期和持续治疗结束后,联合治疗比单独药物治疗更有效(RR 1.61,95%CI 1.23至2.11),并且与心理治疗效果相当(RR 0.96,95%CI 0.79至1.16)。
根据患者的偏好,联合治疗或单独心理治疗均可作为伴有或不伴有广场恐惧症的惊恐障碍的一线治疗方法。